Needham & Company initiates coverage on KaloBios Pharmaceuticals (NASDAQ: KBIO) with a Buy. PT $11.00.

The firm comments, "Kalobios ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE